Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effektivität eines Programms zur Verschreibung von körperlicher Bewegung in der Primärversorgung für Erwachsene ab 65 Jahren: PREFIS-AP

4. November 2026 aktualisiert von: Instituto de Investigación Biomédica de Salamanca

Wirksamkeit eines Programms zur Verschreibung von körperlicher Bewegung in der Primärversorgung zur Verbesserung der körperlichen Fitness und Lebensqualität bei Erwachsenen ab 65 Jahren in einem ländlichen Gesundheitsgebiet: PREFIS-AP randomisierte kontrollierte Studie

This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.

Studienübersicht

Detaillierte Beschreibung

Sedentary behavior is strongly associated with multiple adverse health outcomes, particularly in older adults. Conventional lifestyle advice alone has shown limited effectiveness in increasing physical activity levels. Exercise prescription delivered through structured evaluation, individualized planning, and scheduled follow-up may lead to clinically significant improvements in physical function and quality of life.

This study will recruit 210 adults aged ≥65 years from a rural Primary Care center. Participants will undergo baseline assessments including sociodemographic variables, anthropometric measures, muscle strength (handgrip dynamometry and chair stand test), aerobic capacity (6-minute walk test), muscle mass (calf circumference and ultrasound of rectus femoris), physical activity level (GPAQ), and quality of life (SF-36). After randomization (1:1), the intervention group will receive a personalized exercise prescription generated through the MEDORA Primary Care electronic system and supervised by a qualified Exercise Technician. The control group will receive routine health advice.

After three months, all participants will be reassessed using the same measures. The study will analyze the effect of the intervention on physical fitness, physical activity, muscle mass and function, and quality of life, including sex-specific differences and the role of polypharmacy. The project incorporates a partial masking strategy and uses REDCap for data management and anonymization.

Studientyp

Interventionell

Einschreibung (Geschätzt)

210

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Salamanca
      • Villoría, Salamanca, Spanien, 37339
        • Rekrutierung
        • Centro de Salud de Villoria
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

65 Jahre und älter (Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥ 65 years
  • Motivated to participate and able to provide informed consent
  • Able to attend baseline assessment and follow-up
  • Clinical stability allowing participation in exercise evaluation

Exclusion Criteria:

  • Recent myocardial infarction
  • Unstable angina
  • Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
  • Syncope
  • Acute endocarditis, myocarditis, or pericarditis
  • Severe or symptomatic aortic stenosis
  • Uncontrolled heart failure
  • Recent pulmonary thromboembolism or pulmonary infarction
  • Lower-limb thrombosis
  • Severe aortic stenosis or suspected dissecting aortic aneurysm
  • Uncontrolled asthma
  • Pulmonary edema
  • Acute respiratory failure
  • Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
  • Mental disorder that prevents adequate cooperation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Physical Exercise Prescription Program

Participants receive a 12-week individualized multicomponent Exercise Prescription Programme integrated into routine Primary Care and supported by the MEDORA® electronic health record. Exercise prescription is based on baseline clinical and functional assessment and includes aerobic, resistance, balance and flexibility exercise, with respiratory muscle training when considered clinically indicated. Exercise is performed both independently at home and during supervised group reinforcement sessions available three days per week in municipal sports facilities. During supervised sessions, each participant follows his or her individualized exercise prescription rather than a uniform group exercise programme. Exercise type, intensity, duration, frequency and progression are individualized according to baseline clinical and functional status, tolerance and progression.

Participants receive a structured and individualized 12-week program including:

Aerobic exercise (continuous and interval training, intensity guided by Borg scale)

Strength training using elastic bands (progressively increasing repetitions, series, and load)

Respiratory exercises with pressure-based devices

Flexibility exercises (static stretching routines)

Balance training (single-leg stance, heel-toe walking, eyes-closed tasks)

The program is generated through the MEDORA electronic system after baseline evaluation. A certified Exercise Technician provides instruction, supervision, and progression adjustments.

Exercise type, intensity, duration, frequency and progression are individualized within the exercise-prescription framework according to baseline clinical and functional assessment

Kein Eingriff: Standard Health Advice

Participants allocated to the control group receive usual Primary Care and general physical-activity advice consistent with World Health Organization recommendations. They do not receive an individualized structured exercise prescription, supervised reinforcement sessions, or intervention-specific follow-up. The study did not systematically prescribe control participants to walk briskly for at least 30 minutes per day.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Quality of Life
Zeitfenster: Baseline to 3 months.

Quality of Life will be measured by the SF-36 questionnaire. The SF-36 questionnaire is a widely used, patient-reported questionnaire measuring health-related quality of life. It uses points to assess health, with responses on Likert scales (e.g., 0 to 100) transformed into scores for 8 health domains: physical functioning, role limitations (physical/emotional), bodily pain, general health, vitality, social functioning, and mental health, where higher scores mean better health, ranging from 0 (maximum disability) to 100 (no disability).

Baseline to 3 months.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Physical Activity Level (GPAQ)
Zeitfenster: Baseline to 3 months.

Change in physical activity level as measured by the Global Physical Activity Questionnaire (GPAQ), including time spent in work-related activity, transport-related activity, leisure-time activity, and sedentary behavior. Participants will be classified into WHO categories (high, moderate, or low/inactive) based on standardized scoring procedures.

Baseline to 3 months.
Aerobic Capacity (6-Minute Walk Test)
Zeitfenster: Baseline to 3 months.

Change in functional aerobic capacity assessed by the 6-minute walk test (6MWT). The primary variable will be the total distance walked in meters during 6 minutes. Physiological responses (heart rate, oxygen saturation, perceived exertion using Borg scale) will also be recorded.

Baseline to 3 months.
Muscle Strength - Handgrip Dynamometry
Zeitfenster: Baseline to 3 months.

Change in maximal isometric handgrip strength measured with a JAMAR dynamometer (kg), using the highest value from standardized bilateral measurements. Cut-off values will follow European sarcopenia consensus criteria (<27 kg for men; <16 kg for women).

Baseline to 3 months.
Muscle Strength - Chair Stand Test
Zeitfenster: Baseline to 3 months.

Change in lower-limb functional strength measured by the 30-second chair stand test. The outcome is the total number of complete sit-to-stand repetitions performed within 30 seconds following standardized protocol.

Baseline to 3 months.
Muscle Mass - Calf Circumference
Zeitfenster: Baseline to 3 months.

Change in muscle mass estimated by calf circumference (cm), measured at the widest point of the calf using a flexible tape. A value <31 cm will be considered indicative of potential muscle mass deficit.

Baseline to 3 months.
Muscle Mass - Ultrasound of Rectus Femoris
Zeitfenster: Baseline to 3 months.

Change in quantitative and qualitative muscle parameters assessed by ultrasound of the rectus femoris (muscle thickness, cross-sectional area, and echogenicity), following validated measurement criteria for sarcopenia assessment.

Baseline to 3 months.
Sex Differences in Response to the Exercise Prescription Program (Standardized Change Score)
Zeitfenster: Baseline to 3 months.

This outcome will assess whether biological sex modifies the effect of the intervention on functional and health-related outcomes. Sex-specific differences will be evaluated using standardized change scores (z-scores).

The standardized composite score will be derived from the following previously defined outcome measures:

Muscle strength (handgrip dynamometry (kg) and the 30-second chair stand test) Aerobic capacity (6-minute walk test) Muscle mass, assessed by calf circumference (cm) and ultrasound measurements of rectus femoris muscle thickness Physical activity level, (Global Physical Activity Questionnaire (GPAQ) Health-related quality of life (SF-36 questionnaire) Each variable will be standardized before aggregation to ensure comparability across different units of measurement. The resulting composite score will be compared between men and women to determine if sex influences the magnitude of response to the exercise prescription program.

Baseline to 3 months.
Correlation Between Polypharmacy and Change in Handgrip Strength
Zeitfenster: Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in muscle strength in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Muscle strength will be assessed by handgrip strength, measured in kilograms (kg) using a calibrated hand dynamometer. Change in handgrip strength will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Appendicular Skeletal Muscle Mass
Zeitfenster: Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in muscle mass in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Muscle mass will be assessed as appendicular skeletal muscle mass, measured in kilograms (kg) using dual-energy X-ray absorptiometry (DXA). Change in muscle mass will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Physical Performance
Zeitfenster: Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in physical performance in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Physical performance will be assessed using the Short Physical Performance Battery (SPPB), reported as a total score (points on a standardized scale). Change in SPPB score will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Quality of Life
Zeitfenster: Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in quality of life in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Quality of life will be assessed using the EuroQol-5 Dimension (EQ-5D) questionnaire, reported as a standardized index score. Change in EQ-5D score will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Februar 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

12. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Februar 2026

Zuerst gepostet (Tatsächlich)

6. Februar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • PREFIS-AP

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

IPD-Sharing-Zeitrahmen

Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

IPD-Sharing-Zugriffskriterien

Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ANALYTIC_CODE
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren